A Post Marketing Surveillance to Evaluate the Safety of Desidustat for the Treatment of Anemia in Subjects With Chronic Kidney Disease (CKD).(Real World Evidence Study)

This real-world surveillance study tracks the safety of desidustat — an oral medication recently approved in India for treating anemia in patients with chronic kidney disease (CKD). Anemia in CKD occurs because damaged kidneys produce less of a hormone (erythropoietin) that stimulates red blood cell production. This study monitors patients in real-world clinical practice. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with anemia caused by chronic kidney disease - Your hemoglobin (red blood cell level) is between 7.0 and 11.0 g/dL - You are able to understand the study and give informed consent - You do not have significant vitamin B12 or folate deficiency - If you are on dialysis, you have been receiving it at least twice a week for 12 weeks **You may NOT be eligible if...** - Your anemia is caused by something other than CKD (such as iron deficiency, B12 deficiency, or bleeding) - You have severe uncontrolled heart, liver, or blood pressure conditions - You are pregnant or breastfeeding - You are taking medications that could interfere with the study drug Talk to your doctor to see if this trial is right for you.